Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
Divyanshu Dubey,1 Christopher A Cano,1 Olaf Stuve1–3 1Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, 2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; 3Department of Neurology, Klinikum rechts der Isar...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e848b4d154864ff8a42f4460ff32a5db |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e848b4d154864ff8a42f4460ff32a5db |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e848b4d154864ff8a42f4460ff32a5db2021-12-02T03:41:10ZIntractable and highly active relapsing multiple sclerosis – role of alemtuzumab1178-2021https://doaj.org/article/e848b4d154864ff8a42f4460ff32a5db2015-09-01T00:00:00Zhttps://www.dovepress.com/intractable-and-highly-active-relapsing-multiple-sclerosis-ndash-role--peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Divyanshu Dubey,1 Christopher A Cano,1 Olaf Stuve1–3 1Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, 2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; 3Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany Abstract: Alemtuzumab is a humanized recombinant monoclonal antibody that was recently approved by the US Food and Drug Administration and the European Medicines Agency for the management of relapsing forms of multiple sclerosis (MS). It has been utilized for the management of chronic lymphocytic leukemia, bone marrow and renal transplantation, or graft versus host disease. Because of its immunomodulatory properties, it was brought into clinical development in MS. One Phase II (CAMMS223) and two Phase III clinical trials (CARE-MSI and -II) have evaluated the safety and efficacy of alemtuzumab in patients with relapsing–remitting MS. Even though its efficacy profile and long-lasting effect have attracted much interest among physicians and patients, it has significant potential adverse effects that may limit its use to patients with active disease. Here, we review the history of drug development of alemtuzumab. Furthermore, we outline the postulated mechanisms of action, clinical evidence, and safety of alemtuzumab for its use as a disease-modifying agent in active and highly active MS. Keywords: alemtuzumab, multiple sclerosis, monoclonal antibody, CD52, idiopathic thrombocytopenic purpuraDubey DCano CAStuve ODove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 2405-2414 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Dubey D Cano CA Stuve O Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab |
| description |
Divyanshu Dubey,1 Christopher A Cano,1 Olaf Stuve1–3 1Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, 2Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA; 3Department of Neurology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany Abstract: Alemtuzumab is a humanized recombinant monoclonal antibody that was recently approved by the US Food and Drug Administration and the European Medicines Agency for the management of relapsing forms of multiple sclerosis (MS). It has been utilized for the management of chronic lymphocytic leukemia, bone marrow and renal transplantation, or graft versus host disease. Because of its immunomodulatory properties, it was brought into clinical development in MS. One Phase II (CAMMS223) and two Phase III clinical trials (CARE-MSI and -II) have evaluated the safety and efficacy of alemtuzumab in patients with relapsing–remitting MS. Even though its efficacy profile and long-lasting effect have attracted much interest among physicians and patients, it has significant potential adverse effects that may limit its use to patients with active disease. Here, we review the history of drug development of alemtuzumab. Furthermore, we outline the postulated mechanisms of action, clinical evidence, and safety of alemtuzumab for its use as a disease-modifying agent in active and highly active MS. Keywords: alemtuzumab, multiple sclerosis, monoclonal antibody, CD52, idiopathic thrombocytopenic purpura |
| format |
article |
| author |
Dubey D Cano CA Stuve O |
| author_facet |
Dubey D Cano CA Stuve O |
| author_sort |
Dubey D |
| title |
Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab |
| title_short |
Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab |
| title_full |
Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab |
| title_fullStr |
Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab |
| title_full_unstemmed |
Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab |
| title_sort |
intractable and highly active relapsing multiple sclerosis – role of alemtuzumab |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/e848b4d154864ff8a42f4460ff32a5db |
| work_keys_str_mv |
AT dubeyd intractableandhighlyactiverelapsingmultiplesclerosisndashroleofalemtuzumab AT canoca intractableandhighlyactiverelapsingmultiplesclerosisndashroleofalemtuzumab AT stuveo intractableandhighlyactiverelapsingmultiplesclerosisndashroleofalemtuzumab |
| _version_ |
1718401705419210752 |